Alongside the interim results, Deltex has announced the outcome of a strategic review that has resulted in £2m of annualised cost savings to contribute to net cash generation and P&L break even in 2019. While the top-line trends have been disappointing in H1 2018, the new strategy to focus on increasing consumables use at existing customers requiring a smaller sales force should drive improved profitability.
24 Sep 2018
Interim results - Strategic review drives cost reductions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interim results - Strategic review drives cost reductions
Deltex Medical Group plc (DEMG:LON) | 0.1 0 3.8% | Mkt Cap: 2.56m
- Published:
24 Sep 2018 -
Author:
Andrew Simms -
Pages:
4
Alongside the interim results, Deltex has announced the outcome of a strategic review that has resulted in £2m of annualised cost savings to contribute to net cash generation and P&L break even in 2019. While the top-line trends have been disappointing in H1 2018, the new strategy to focus on increasing consumables use at existing customers requiring a smaller sales force should drive improved profitability.